153 related articles for article (PubMed ID: 30719139)
1. Elevated Serum Sialic Acid Levels Predict Prostate Cancer As Well As Bone Metastases.
Zhang C; Yan L; Song H; Ma Z; Chen D; Yang F; Fang L; Li Z; Li K; Li D; Yu N; Liu H; Xu Z
J Cancer; 2019; 10(2):449-457. PubMed ID: 30719139
[No Abstract] [Full Text] [Related]
2. Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer.
Sun J; Tian T; Wang N; Jing X; Qiu L; Cui H; Liu Z; Liu J; Yan L; Li D
Front Endocrinol (Lausanne); 2024; 15():1338420. PubMed ID: 38384968
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Role of Neutrophil to Lymphocyte Ratio or Platelet to Lymphocyte Ratio in Prediction of Bone Metastasis of Prostate Cancer.
Zhang JY; Ge P; Zhang PY; Zhao M; Ren L
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115239
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of the carboxy-terminal propeptide of type I procollagen and the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen as markers of bone metastases in patients with prostate carcinoma.
Hosoya Y; Arai K; Honda M; Sumi S; Yoshida K
Eur Urol; 1997; 31(2):220-3. PubMed ID: 9076470
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the value of Preoperative Sialic Acid Levels in Diagnosis and Localization of Urothelial Tumors.
Chen D; Li D; Cui Z; Zhang C; Zhang Z; Yan L
J Cancer; 2021; 12(16):5066-5075. PubMed ID: 34234875
[No Abstract] [Full Text] [Related]
7. Identification of characteristic metabolic panels for different stages of prostate cancer by
Zhang X; Xia B; Zheng H; Ning J; Zhu Y; Shao X; Liu B; Dong B; Gao H
J Transl Med; 2022 Jun; 20(1):275. PubMed ID: 35715864
[TBL] [Abstract][Full Text] [Related]
8. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
Yoshida K; Sumi S; Arai K; Koga F; Umeda H; Hosoya Y; Honda M; Yano M; Moriguchi H; Kitahara S
Cancer; 1997 Nov; 80(9):1760-7. PubMed ID: 9351545
[TBL] [Abstract][Full Text] [Related]
9. Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection.
Ferrer-Batallé M; Llop E; Ramírez M; Aleixandre RN; Saez M; Comet J; de Llorens R; Peracaula R
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420168
[TBL] [Abstract][Full Text] [Related]
10. Progression of prostate cancer: diagnostic and prognostic utility of prostate-specific antigen, alpha2-macroglobulin, and their complexes.
Kanoh Y; Ohtani N; Ohara T; Mashiko T; Ohtani S; Egawa S; Baba S; Ohtani H
Oncol Rep; 2001; 8(3):515-9. PubMed ID: 11295072
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment Serum Cystatin C Levels Predict Renal Function, but Not Tumor Characteristics, in Patients with Prostate Neoplasia.
Yang F; Li D; Di Y; Zhang Y; Zang Y; Ren J; Yan L; Zhou Z; Liu H; Xu Z
Biomed Res Int; 2017; 2017():7450459. PubMed ID: 28812020
[TBL] [Abstract][Full Text] [Related]
12. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
13. Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander?
Shah R; Mucci NR; Amin A; Macoska JA; Rubin MA
Am J Pathol; 2001 May; 158(5):1767-73. PubMed ID: 11337374
[TBL] [Abstract][Full Text] [Related]
14. BPH: a tell-tale sign of prostate cancer? Results from the Prostate Cancer and Environment Study (PROtEuS).
Boehm K; Valdivieso R; Meskawi M; Larcher A; Sun M; Sosa J; Blanc-Lapierre A; Weiss D; Graefen M; Saad F; Parent MÉ; Karakiewicz PI
World J Urol; 2015 Dec; 33(12):2063-9. PubMed ID: 25824539
[TBL] [Abstract][Full Text] [Related]
15. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer.
Montie JE; Pienta KJ
Urology; 1994 Jun; 43(6):892-9. PubMed ID: 7515207
[TBL] [Abstract][Full Text] [Related]
16. Oxidative stress parameters in patients with prostate cancer, benign prostatic hyperplasia and asymptomatic inflammatory prostatitis: A prospective controlled study.
Kaya E; Ozgok Y; Zor M; Eken A; Bedir S; Erdem O; Ebiloglu T; Ergin G
Adv Clin Exp Med; 2017 Oct; 26(7):1095-1099. PubMed ID: 29211357
[TBL] [Abstract][Full Text] [Related]
17. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
18. Systemic Inflammatory Response in Predicting Prostate Cancer: The Diagnostic Value of Neutrophil-To-Lymphocyte Ratio.
Adhyatma KP; Prapiska FF; Siregar GP; Warli SM
Open Access Maced J Med Sci; 2019 May; 7(10):1628-1630. PubMed ID: 31210812
[TBL] [Abstract][Full Text] [Related]
19. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
20. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
